Almac Pharma Services, a member of the Almac Group providing innovative pharmaceutical development, manufacture and commercial services, has announced it is entering the final
Custom built 100,000sq ft GMP facility will further support clinical and commercial partnerships
Almac Pharma Services, a member of the Almac Group providing innovative pharmaceutical development, manufacture and commercial services, has announced it is entering the final phase of a £65 million investment to expand its existing drug product manufacturing capabilities at its global headquarter site in Craigavon, Northern Ireland.
Responding to increased demand for product development and manufacturing services, the expansion will support the company’s existing global partnerships and reinforce its strong track record of providing superior drug development, manufacture and commercial packaging and distribution services.
The custom built GMP facility will come on-line in Q3 2024 and will extend to 100,000ft2/ 9,300m2 with bespoke, state-of-the-art production suites, lineside warehousing for ambient, refrigerated and frozen storage and associated support areas.
The new facility, which will primarily support solid oral dose products, will complement Almac’s existing capabilities in this area. It includes an extension to current scales of production for products involving potent and highly potent APIs. The high-specification production suites, which will be operated by Almac’s expert scientific and operational teams, have been designed with flexibility and a wide range of uses in mind. This offers opportunities for clients to install bespoke technology particular to their individual and emerging pipeline needs.
Operating out of four sites across Europe and the US with over 1,500 employees, Almac Pharma Services also has vast experience in providing a range of complementary packaging and delivery solutions with advanced systems and processes for managing the launch and ongoing supply of highly complex and Just-In-Time supply chain models. The fully integrated service offered by Almac Pharma Services delivers end-to-end solutions supporting clients as they move from early to late-stage development through to launch and commercial supply across global markets.
John McQuaid, President & Managing Director, Almac Pharma Services commented: “In the past five years we have experienced increased demand for our pharmaceutical development, commercial manufacturing and packaging solutions. Our strong track record and expertise in handling complex and challenging molecules across a range of batch scales enables us to offer clients a variety of solutions to meet the individual requirements of their products.
“This significant investment demonstrates our commitment to offering enhanced drug development and manufacturing solutions and further establishes Almac Pharma Services as a long-term partner for commercial supply of novel therapies. The new facility adds more capacity and additional capabilities including larger scale potent handling. We can tailor these capabilities to suit individual products as we work in partnership with our clients to bring important therapies to the patients we serve.”
#ENDS#
About Almac Pharma Services
Tailormade pharmaceutical development and commercial solutions
With over 50 years’ experience, Almac Pharma Services is a world leading outsourcing partner to the global pharmaceutical and biotechnology industry.
Employing over 1,500 highly skilled individuals across 4 locations in Europe and the US, the company provides tailored, quality-led and timely solutions from early and late phase pharmaceutical development, clinical and commercial drug product manufacture, product launch through to commercial packaging and global distribution.
About Almac Group
The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Its innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, analytical services, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation which has grown organically, now employing 7,000 highly skilled personnel across 18 facilities including Europe, the USA and Asia.
To keep up to date with latest news, follow us on Twitter and LinkedIn or visit almacgroup.com.